Scarica l'app Stockscreener
134.71
0.45%
0.6378
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$134.07
Aprire:
$135
Volume 24 ore:
461.29K
Relative Volume:
0.41
Capitalizzazione di mercato:
$13.54B
Reddito:
$2.86B
Utile/perdita netta:
$478.60M
Rapporto P/E:
28.86
EPS:
4.6676
Flusso di cassa netto:
$748.70M
1 W Prestazione:
+5.12%
1M Prestazione:
+2.34%
6M Prestazione:
-12.41%
1 anno Prestazione:
+22.71%
Intervallo 1D:
$134.10
$137.15
Intervallo di 1 settimana:
$126.48
$137.15
Portata 52W:
$115.66
$160.18
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Nome
Neurocrine Biosciences Inc
Settore
Telefono
(858) 617-7600
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, TEVA, HLN, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
134.65 | 13.49B | 2.86B | 478.60M | 748.70M | 4.6676 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.64 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.63 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.20 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
578.34 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-04-15 | Aggiornamento | Needham | Hold → Buy |
| 2025-04-14 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-08-29 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Ripresa | Citigroup | Neutral |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-10-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Reiterato | Mizuho | Neutral |
| 2023-07-24 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Aggiornamento | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-03-30 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Iniziato | UBS | Buy |
| 2022-09-26 | Iniziato | Wells Fargo | Equal Weight |
| 2022-06-06 | Ripresa | Jefferies | Buy |
| 2022-03-03 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-01-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Iniziato | BMO Capital Markets | Underperform |
| 2021-11-17 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-08-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Ripresa | Goldman | Neutral |
| 2021-05-06 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Iniziato | Raymond James | Outperform |
| 2020-09-30 | Iniziato | The Benchmark Company | Hold |
| 2020-08-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Downgrade | Goldman | Buy → Neutral |
| 2020-06-09 | Iniziato | Wedbush | Outperform |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-02-24 | Iniziato | William Blair | Outperform |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2020-02-05 | Reiterato | H.C. Wainwright | Buy |
| 2019-12-13 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-05 | Iniziato | Guggenheim | Neutral |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-22 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-02-06 | Reiterato | BofA/Merrill | Buy |
| 2019-01-23 | Downgrade | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Iniziato | Goldman | Buy |
| 2018-11-21 | Iniziato | Canaccord Genuity | Buy |
Mostra tutto
Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie
Neurocrine executives take Bank of America health conference stage - Stock Titan
Neurocrine Biosciences to Present at the Bank of America Health Care Conference 2026 - PR Newswire
MSN Money - MSN
Neurocrine begins phase 1 trial of obesity drug NBIP-2118 By Investing.com - Investing.com Australia
Should Durable Two-Year CRENESSITY CAH Data Shift Neurocrine Biosciences’ (NBIX) Long-Term Investment Narrative? - simplywall.st
Survey: adults with tardive dyskinesia missed 8 work hours a week - Stock Titan
Neurocrine Biosciences Announces New Survey Results Showing Significant Burden of Tardive Dyskinesia on Employment - Yahoo Finance
Neurocrine begins phase 1 trial of obesity drug NBIP-2118 - Investing.com
Neurocrine Biosciences announces initiation of phase 1 clinical study evaluating NBIP-'2118, a corticotropin-releasing factor type 2 receptor agonist - marketscreener.com
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'2118, a Corticotropin-Releasing Factor Type 2 Receptor Agonist - PR Newswire
Trading Systems Reacting to (NBIX) Volatility - Stock Traders Daily
Horizon Investments LLC Buys 16,474 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Will Two-Year CRENESSITY Data in CAH Change Neurocrine Biosciences' (NBIX) Narrative? - Yahoo Finance
Neurocrine’s Two Year CAH Data May Reframe NBIX Valuation Story - simplywall.st
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Short Interest Up 23.9% in April - MarketBeat
Neurocrine presents two-year data on CAH treatment Crenessity - Investing.com UK
Neurocrine presents two-year data on CAH treatment Crenessity By Investing.com - Investing.com Canada
Neurocrine shows sustained pediatric results for CRENESSITY in two-year study - StreetInsider
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hy - PR Newswire
UBS Group AG Acquires 618,956 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) Announces First Presentation of New Two-Year Data From Phase 3 CAHtalyst® Adult Study - Insider Monkey
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026 - GlobeNewswire Inc.
Vanguard (NBIX) reports 5.23% ownership — 5.26M shares disclosed - Stock Titan
NBIX Stock Price, Quote & Chart | NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - ChartMill
Neurocrine-Soleno deal garners Wall Street praise — analyst applauds business development acumen - MSN
Earnings Preview: NBIX to Report Financial Results Post-market on May 05 - Moomoo
Neurocrine to buy Soleno Therapeutics for $2.9 billion - MSN
Neurocrine announces tardive dyskinesia scale threshold study - Investing.com UK
Soleno Therapeutics stock rallies 56.4% in a week: Here's why - MSN
Neurocrine publishes tardive dyskinesia scale validation research - StreetInsider
Neurocrine announces tardive dyskinesia scale threshold study By Investing.com - Investing.com India
Neurocrine Biosciences Announces Publication Establishing Clinically Meaningful Improvement Threshold for the Tardive Dyskinesia Impact Scale - ChartMill
Neurocrine to buy Soleno Therapeutics for $53/share in cash - MSN
AMG National Trust Bank Acquires Shares of 12,326 Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Soleno Therapeutics rallies on report of $2.5B Neurocrine buyout talks - MSN
Neurocrine, Soleno HSR waiting period expired April 27 - MLex
Neurocrine Biosciences-Soleno Therapeutics HSR waiting period expired April 27 - MLex
Neurocrine Biosciences (NBIX) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
Neurocrine (NASDAQ: SLNO) to acquire Soleno for $53.00 per share after HSR clearance - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Shares Purchased by Pictet Asset Management Holding SA - MarketBeat
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teacher Retirement System of Texas - MarketBeat
37,800 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Gray Foundation - MarketBeat
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis: Unlocking a 45% Upside Potential Amid Strong Buy Ratings - DirectorsTalk Interviews
A Look At Neurocrine Biosciences (NBIX) Valuation After CRENESSITY Phase 3 CAHtalyst Adult Results - simplywall.st
Wall Street analysts think Neurocrine (NBIX) could surge 38.79%: Read this before placing a bet - MSN
Neurocrine to buy Soleno for treatment for rare disease that causes relentless hunger - MSN
Munich Reinsurance Co Stock Corp in Munich Buys 10,168 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neurocrine Biosciences Inc Azioni (NBIX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,133 |
0 |
39,230 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
3,352 |
0 |
7,969 |
| Boyer David W. | Chief Corp. Affairs Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
1,600 |
0 |
6,313 |
| Gano Kyle | Chief Executive Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,807 |
0 |
147,610 |
| Gano Kyle | Chief Executive Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
4,907 |
0 |
146,661 |
| Onyia Jude | Chief Scientific Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
5,407 |
0 |
21,066 |
| Onyia Jude | Chief Scientific Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,560 |
0 |
18,537 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
4,044 |
0 |
56,664 |
| BENEVICH ERIC | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
0.00 |
2,005 |
0 |
54,760 |
| Cooke Julie | Chief Human Resources Officer |
Feb 13 '26 |
Option Exercise |
0.00 |
2,911 |
0 |
30,395 |
2.63%
0.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):